Stock comparison
AstraZeneca
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AZN
AstraZeneca
Market cap
$290.06B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
AstraZeneca AZN
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AZN | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 65C | GMAB |
| Benjamin Graham | 73B | 64C | AZN |
| Philip Fisher | 64C | 48D | AZN |
| Peter Lynch | 63C | 25F | AZN |
| Joel Greenblatt | 51C | 76B | GMAB |
| Charlie Munger | 62C | 68C | GMAB |
| Terry Smith | 60D | 71C | GMAB |
Side-by-side metrics
| Metric | AZN | GMAB |
|---|---|---|
| Market cap | $290.06B | $16.5B |
| P/E (TTM) | 27.6x | 6.2x |
| EV/EBIT | 23.0x | 12.0x |
| ROIC (TTM) | 12.88% | 43.78% |
| Gross margin | 79.71% | 93.88% |
| Net margin | 17.19% | 18.23% |
| Revenue CAGR 5y | 11.93% | -18.45% |
| EPS CAGR 5y | 2.01% | -23.48% |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 1.7% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AZN leads on
- Revenue CAGR 5y11.93%vs -18.45%+165%
- EPS CAGR 5y2.01%vs -23.48%+112%
- Dividend yield1.7%vs 0.0%+100%
- Market cap$290.06Bvs $16.5B+94%
GMAB leads on
- Debt / Equity0.1xvs 0.7x+90%
- P/E (TTM)6.2xvs 27.6x+78%
- ROIC (TTM)43.78%vs 12.88%+71%
- EV/EBIT12.0xvs 23.0x+48%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.